The prevalence of depression
Depression is a prevalent diagnosis in the HIV-infected population. According to a study by Verispan, depression is the most prevalent concomitant diagnosis in the Caucasian HIV-infected population, and the second-most prevalent concomitant diagnosis in the African-American HIV-infected population. In another recent survey of 136 HIV-treating physicians, ~80% of HIV-infected patients frequently suffer from symptoms of depression and anxiety.
Depression affects HIV and its treatment
Depression:
- Negatively impacts HIV-related mortality and disease progression Negatively impacts immune system function
- Is a high priority for physicians in making treatment decisions for patients with HIV
Adherence
Depression, along with generalized anxiety and panic disorder, is correlated with non-adherence to ARV medications.
Depression can instigate a cycle of non adherence which may ultimately lead to the loss of a treatment option.
DiMatteo MR, Lepper H, Croghan TW. Arch Intern Med. 2000;160:2101-2107.
Managing depression in HIV patients
- Talk with your patients about depression
- Greater communication between patient and healthcare provider is associated with greater adherence to treatment
- Screen for depression. There are a variety of tools and programs that can be useful to help patients understand the impact depression may play in their overall treatment paradigm
- Other treatment factors should also be discussed where appropriate
Please consult Full Prescribing Information, including boxed WARNING, Medication Guide, and Important Safety Information for VIRAMUNE.
